Managing Partner
- sander.slootweg@forbion.com
- Download vCard 
Sander is Managing Partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006.
Sander joined ABN AMRO Private Equity in 1999. Prior to this, Sander was at the Financial Institutions Relationship Management Group, which he joined in 1994 as an assistant global relationship manager for financial institutions in the Americas. From 1997-1999 he was responsible for all Financial Institutions in Argentina, Brazil and Chile, operating out of the Miami office.
Sander began his career at ABN AMRO in 1993 as a management trainee for the Investment Banking operations. After completing his traineeship, he was briefly part of the Equity Capital Markets Group at which he was involved in the largest Dutch IPO to date: the privatization of KPN, the Dutch national telephone company.
Sander serves on the boards of Pulmagen, Xention, Provesica and Biovex.
Sander has also served on the boards of AM Pharma B.V., Cambridge Drug Discovery (now Galapagos), Etiologics Ltd (now Argenta), Pieris, ImpellaCardioSystems, Alantos Pharmaceuticals (sold to Amgen in 2007) and Cilian (now Bioceros), Argos Therapeutics , Ardana and GlycArt (sold to Roche in 2005), Amsterdam Molecular Therapeutics (IPO 2007) and Fovea (sold to sanofi-aventis in 2009).
Sander has degrees in Business Administration (Nijenrode University, 1989) and Business Economics (Free University of Amsterdam, 1992). He wrote his graduation thesis on different ways of applying complex valuation models in M&A transactions.
